You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Bone density conservation agents
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:othertreatments:boneagents [01.08.2010] – paulalberthome:othertreatments:boneagents [01.08.2010] – paulalbert
Line 6: Line 6:
  
 A variety of medications including the bisphosphonates have been touted to conserve or increase bone mass. These drugs have a number of side effects and are known or suspected to interfere with proper immune function.  A variety of medications including the bisphosphonates have been touted to conserve or increase bone mass. These drugs have a number of side effects and are known or suspected to interfere with proper immune function. 
- 
- 
 ===== Bisphosphonates ===== ===== Bisphosphonates =====
  
Line 16: Line 14:
   * atrial fibrillation – Numerous studies have shown that the frequency of atrial fibrillation increases with increasing age in both men and women. Data from the Framingham Heart Study showed a greater biennial incidence of AF with increasing age, with the odds ratio rising by a factor of 2.2 for every additional 10 years of age.(({{pubmed>long:8114238}}))    * atrial fibrillation – Numerous studies have shown that the frequency of atrial fibrillation increases with increasing age in both men and women. Data from the Framingham Heart Study showed a greater biennial incidence of AF with increasing age, with the odds ratio rising by a factor of 2.2 for every additional 10 years of age.(({{pubmed>long:8114238}})) 
   * calcium deposition in the soft tissues(({{pubmed>long: 14523647}}))   * calcium deposition in the soft tissues(({{pubmed>long: 14523647}}))
 +  * osteonecrosis of the jaw, i.e. bone death
   * reduced organ function, e.g. renal dysfunction or failure   * reduced organ function, e.g. renal dysfunction or failure
-  * osteonecrosis of the jaw, i.e. bone death 
  
 Those patients with elevated 1,25-D – which is [[home:pathogenesis:vitamind:metabolism#evidence_for_high_1_25-d_in_patients_with_chronic_disease|very common]] among those suffering from Th1 disease – seem particularly predisposed to the adverse effects of dysregulated calcium metabolism. Those patients with elevated 1,25-D – which is [[home:pathogenesis:vitamind:metabolism#evidence_for_high_1_25-d_in_patients_with_chronic_disease|very common]] among those suffering from Th1 disease – seem particularly predisposed to the adverse effects of dysregulated calcium metabolism.
home/othertreatments/boneagents.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.